Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Retained Earnings (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Retained Earnings for 4 consecutive years, with $2000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Retained Earnings fell 90.91% year-over-year to $2000.0, compared with a TTM value of $2000.0 through Sep 2025, down 90.91%, and an annual FY2024 reading of -$2.1 billion, down 4.34% over the prior year.
  • Retained Earnings was $2000.0 for Q3 2025 at Atara Biotherapeutics, up from -$2.0 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $22000.0 in Q3 2024 and bottomed at -$2.1 billion in Q4 2024.
  • Average Retained Earnings over 4 years is -$1.4 billion, with a median of -$1.8 billion recorded in 2023.
  • Peak annual rise in Retained Earnings hit 100.0% in 2024, while the deepest fall reached 216400.64% in 2024.
  • Year by year, Retained Earnings stood at -$1.7 billion in 2022, then dropped by 16.31% to -$2.0 billion in 2023, then fell by 4.34% to -$2.1 billion in 2024, then soared by 100.0% to $2000.0 in 2025.
  • Business Quant data shows Retained Earnings for ATRA at $2000.0 in Q3 2025, -$2.0 billion in Q2 2025, and -$2.0 billion in Q1 2025.